Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Heidelberg Pharma AG (HPHA.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
4.6900+0.0300 (+0.64%)
At close: 05:36PM CEST
Advertisement

Heidelberg Pharma AG

Gregor-Mendel-Strasse 22
Ladenburg 68526
Germany
49 6203 1009 0
https://heidelberg-pharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Jan Schmidt-BrandCEO, CFO & Member of the Exec. Management Board360.77kN/A1958
Prof. Andreas PahlChief Scientific Officer & Member of the Exec. Management Board328.28kN/AN/A
Sylvia WimmerSr. Mang. of Corp. CommunicationsN/AN/AN/A
Dr. Andras StrasszChief Medical OfficerN/AN/AN/A
Dr. Mathias LocherChief Devel. OfficerN/AN/AN/A
Dr. George Octavian BadescuChief Bus. OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Corporate Governance

Heidelberg Pharma AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement